Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CMPS 
Compass Pathways Plc (CMPS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: CMPS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $17
1 Year Target Price $17
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.69% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 488.73M USD | Price to earnings Ratio - | 1Y Target Price 17 |
Price to earnings Ratio - | 1Y Target Price 17 | ||
Volume (30-day avg) 11 | Beta 1.94 | 52 Weeks Range 2.25 - 7.08 | Updated Date 12/4/2025 |
52 Weeks Range 2.25 - 7.08 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.72 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.43% | Return on Equity (TTM) -205.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 337973753 | Price to Sales(TTM) - |
Enterprise Value 337973753 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.51 | Shares Outstanding 96017044 | Shares Floating 67382841 |
Shares Outstanding 96017044 | Shares Floating 67382841 | ||
Percent Insiders 12.12 | Percent Institutions 60.06 |
Upturn AI SWOT
Compass Pathways Plc
Company Overview
History and Background
Compass Pathways Plc was founded in 2016. It is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company focuses on developing psilocybin therapy for treatment-resistant depression (TRD) and other mental health disorders.
Core Business Areas
- Pharmaceutical Development: Focuses on the research, development, and clinical trials of COMP360, a proprietary formulation of psilocybin, for various mental health indications.
- Therapy Services: Develops and implements standardized therapy protocols to be used in conjunction with COMP360 treatment.
- Digital Health: Developing digital tools to support patients and therapists throughout the treatment journey.
Leadership and Structure
The leadership team includes Kabir Nath (CEO), Guy Goodwin (Chief Medical Officer), and other experienced executives in the pharmaceutical and healthcare industries. The company has a board of directors overseeing its strategic direction and operations.
Top Products and Market Share
Key Offerings
- COMP360: COMP360 is Compass Pathways' lead investigational drug, a proprietary formulation of psilocybin. It is currently in Phase III clinical trials for treatment-resistant depression (TRD). Market share data is not yet available as it is not FDA approved. Potential competitors include other companies developing psychedelic-assisted therapies such as MindMed (MNMD), Atai Life Sciences (ATAI), and GH Research (GHRS).
Market Dynamics
Industry Overview
The mental health market is experiencing significant growth, driven by increasing awareness, prevalence of mental health disorders, and demand for innovative treatments. There is growing interest in psychedelic-assisted therapies as potential solutions for unmet needs in mental health.
Positioning
Compass Pathways is a leading company in the psychedelic-assisted therapy space, particularly focused on psilocybin therapy for TRD. It has a first-mover advantage and a strong intellectual property position.
Total Addressable Market (TAM)
The TAM for treatment-resistant depression is estimated to be billions of dollars annually. Compass Pathways is positioned to capture a significant portion of this market if COMP360 receives regulatory approval.
Upturn SWOT Analysis
Strengths
- First-mover advantage in psilocybin therapy
- Strong intellectual property portfolio
- Experienced management team
- Advanced clinical trial progress (Phase III)
- Established relationships with regulators and researchers
Weaknesses
- Regulatory uncertainty surrounding psychedelic therapies
- High clinical trial costs and risk of failure
- Dependence on a single key product (COMP360)
- Potential for adverse effects associated with psilocybin
- Public perception and stigma associated with psychedelics
Opportunities
- Expansion into other mental health indications (e.g., PTSD, anxiety)
- Strategic partnerships with pharmaceutical companies
- Development of digital health tools to enhance treatment
- Advocacy for regulatory changes to facilitate access to psychedelic therapies
- Global expansion
Threats
- Competition from other companies developing psychedelic therapies
- Changes in regulatory landscape that could hinder approval
- Negative clinical trial results
- Generic competition if intellectual property is not adequately protected
- Ethical concerns regarding the use of psychedelics
Competitors and Market Share
Key Competitors
- MNMD
- ATAI
- GHRS
Competitive Landscape
Compass Pathways is a leader in the field, but faces increasing competition from other companies developing psychedelic therapies. The competitive landscape is characterized by intense R&D efforts and a race to obtain regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by clinical trial progress and investor interest in the psychedelic therapy space.
Future Projections: Future growth depends on the successful completion of Phase III trials for COMP360, regulatory approval, and market adoption. Analyst estimates vary widely depending on these factors.
Recent Initiatives: Recent initiatives include expanding clinical trials to additional sites, developing digital tools, and engaging with regulatory agencies.
Summary
Compass Pathways is a pioneering company in the psychedelic therapy field, particularly psilocybin for treatment-resistant depression. Its focus on COMP360 and advanced clinical trials gives it a strong position, but its future success hinges on regulatory approval and acceptance. The company faces challenges with regulatory uncertainty, competition, and public perception, making it a high-risk, high-reward investment. Positive clinical trial results could be a boon, and regulatory setbacks or strong competition is something to look out for.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Compass Pathways Plc SEC Filings
- Company Press Releases
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on available data and is subject to change without notice. Investing in clinical-stage pharmaceutical companies involves significant risks, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Compass Pathways Plc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-18 | CEO & Director Mr. Kabir Kumar Nath M.A., M.B.A. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 166 | Website https://compasspathways.com |
Full time employees 166 | Website https://compasspathways.com | ||
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.